← Eichor
Study identifier: NCT07473167 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Condition: Relapsed Large B-cell Lymphoma · Refractory Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma (DLBCL)  ·  Sponsor: TICAROS Co., Ltd.

PhasePhase 1/Phase 2
Planned participants98
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.

This description comes directly from the study's public registry record.

Talk to the study team

Ah hyun Lim  ·  82+1029985238  ·  ah.lim@ticaros.com

admin  ·  admin@ticaros.com

Always discuss trial participation with your own doctor first.

Locations (1)

Seoul National University HospitalSeoul, Seoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07473167